Business Context and Reporting Period
This Form 6-K filing by Alpha Tau Medical Ltd. covers the month of June 2026, specifically reporting on transactions executed on June 2, 2026, and announced via press release on June 3, 2026. The filing details a strategic partnership and capital raise involving the Company's lead product candidate, Alpha DaRT.
Key Financial Metrics and Transaction Details
The filing does not provide standard financial statements (revenue, profit, cash flow, or margins) for the period. Instead, it outlines significant contractual financial commitments and proceeds:
- Upfront Payment: Tolmar International Ltd. will make an initial payment of $15.0 million to expand manufacturing capabilities for Alpha DaRT.
- Milestone Payments: Tolmar may pay up to an aggregate of $161.5 million in clinical, regulatory, and commercial milestones for the first prostate cancer indication.
- Revenue Share: Tolmar will pay the Company for the supply of Alpha DaRT at 60% of net sales, subject to adjustments.
- Private Placement Proceeds: The Company expects gross proceeds of $20.0 million from the sale of 1,668,057 ordinary shares at $11.99 per share.
- Option Exercise Payment: An additional $5.0 million payment is required if Tolmar exercises its option to expand into bladder cancer.
Material Changes and Strategic Developments
The primary material change is the entry into the "Tolmar Agreements," granting Tolmar exclusive U.S. commercialization rights for Alpha DaRT for prostate cancer. Key terms include:
- Commercial Rights: Tolmar holds exclusive rights in the U.S. for prostate cancer, with an option to expand to bladder cancer and negotiate rights in Central/South America.
- Equity Investment: Tolmar purchased shares in a private placement at a 25% premium to the 30-day volume-weighted average price (VWAP).
- Term: The agreements expire 20 years following the first commercial sale of Alpha DaRT for prostate cancer in the U.S., unless terminated earlier.
Outlook, Risks, and Contingencies
Management intends to use the net proceeds from the private placement for general corporate purposes. The filing highlights several risks and termination contingencies:
- Termination Rights: Tolmar may terminate the agreements without cause at any time with prior written notice. The Company may terminate if Tolmar is acquired by a competitor, challenges IP rights, or violates laws.
- IP Dependency: The agreements may be terminated if the Company cannot secure necessary third-party intellectual property rights.
- Regulatory Status: The shares sold in the private placement are not registered under the Securities Act of 1933 and are subject to resale restrictions.
Investor Verification Checklist
- Verify the closing date and actual receipt of the $15.0 million upfront payment and $20.0 million private placement proceeds.
- Confirm the specific terms and conditions attached to the 60% net sales royalty rate.
- Review the detailed commercialization plan Tolmar must follow to ensure "commercially reasonable efforts" are defined.
- Assess the status of third-party intellectual property rights required for the exploitation of Alpha DaRT.
- Monitor the exercise of the bladder cancer option and the associated $5.0 million payment and additional share purchase.